Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Solvay
Solvay Pharmaceuticals settles lawsuit against pseudo-generics to its Creon Minimicrospheres
August 18th, 2006
Solvay announced that its United States subsidiary Solvay Pharmaceuticals, Inc. has settled a lawsuit against Global Pharmaceuticals and Impax Laboratories, Inc. alleging that the companies falsely advertised and marketed their products as generic equivalents to and substitutes for Solvay Pharmaceuticals' Creon Minimicrospheres (pancrelipase delayed-release capsules, USP). Under the terms of the settlement, Global Pharmaceuticals and Impax Laboratories will pay US$23 million to Solvay Pharmaceuticals, Inc., of which US$12 million was paid initially. The remaining US$11 million will be paid to Solvay and accounted for over a 6-year period. The terms...
Source: Biotech Law Weekly (2006-08-18)
|
